Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma
暂无分享,去创建一个
T. Spector | N. Segata | R. Fehrmann | G. Hospers | E. de Vries | R. Weersma | M. Falchi | V. Bataille | P. Lorigan | M. Harland | A. Visconti | J. Sacco | J. Newton-Bishop | A. M. Thomas | J. Björk | Mark Harries | P. Nathan | S. Papa | R. Board | L. Taams | H. Shaw | L. Bolte | Karla A. Lee | N. Rossi | M. V. Bermudez | Laura Kist de Ruijter | Niccolo' Rossi
[1] D. Schadendorf,et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] I. Zalaudek,et al. Epidemiology and Risk Factors of Melanoma: A Review , 2021, Dermatology practical & conceptual.
[3] P. Libby,et al. Interleukins in cancer: from biology to therapy , 2021, Nature Reviews Cancer.
[4] F. Hodi,et al. Ipilimumab, nivolumab and tocilizumab as first-line therapy for advanced melanoma. , 2021 .
[5] David M. Woods,et al. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition , 2020, Journal for immunotherapy of cancer.
[6] J. Utikal,et al. Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] You-hong Cui,et al. CCL8 secreted by tumor-associated macrophages promotes invasion and stemness of glioblastoma cells via ERK1/2 signaling , 2019, Laboratory Investigation.
[8] Yan-Mei Zhang,et al. Hypoxia-induced ZEB1 promotes cervical cancer progression via CCL8-dependent tumour-associated macrophage recruitment , 2019, Cell Death & Disease.
[9] G. Freeman,et al. Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy. , 2019, Immunity.
[10] E. Jaffee,et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. , 2019, JCI insight.
[11] G. Linette,et al. A Single Dose of Neoadjuvant PD-1 Blockade Predicts Clinical Outcomes in Resectable Melanoma , 2019, Nature Medicine.
[12] K. Wakamatsu,et al. Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma. , 2019, Journal of dermatological science.
[13] J. Bluestone,et al. Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer , 2018, Front. Med..
[14] M. Czyz,et al. HGF/c-MET Signaling in Melanocytes and Melanoma , 2018, International journal of molecular sciences.
[15] D. Schadendorf,et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. , 2018, The Lancet. Oncology.
[16] P. Ascierto,et al. Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study , 2018, Cancer Immunology, Immunotherapy.
[17] Merrick I Ross,et al. Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma , 2018, Nature Medicine.
[18] Reinhard Dummer,et al. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy , 2018, Nature Network Boston.
[19] M A Weinstock,et al. Epidemiology of melanoma. , 2017, Cancer treatment and research.
[20] David M. Woods,et al. Predictors of responses to immune checkpoint blockade in advanced melanoma , 2017, Nature Communications.
[21] J. Lunceford,et al. IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade , 2017, The Journal of clinical investigation.
[22] R. Halaban,et al. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] Y. Fujisawa,et al. Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma , 2017, Cancer science.
[24] Jedd D. Wolchok,et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response , 2017, Nature.
[25] Erich P Huang,et al. RECIST 1.1-Update and clarification: From the RECIST committee. , 2016, European journal of cancer.
[26] C. Berking,et al. Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab , 2016, Clinical Cancer Research.
[27] J. Sosman,et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.
[28] S. Gabriel,et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.
[29] Carlo Riccardo Rossi,et al. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. , 2014, In vivo.
[30] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.
[31] J. Stenvang,et al. Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability , 2014, PloS one.
[32] M. Kivimäki,et al. Chronic inflammation as a determinant of future aging phenotypes , 2013, Canadian Medical Association Journal.
[33] H. Schmidt,et al. Interleukin-6 and melanoma , 2012, Melanoma research.
[34] J. Landsberg,et al. Neonatal UVB exposure accelerates melanoma growth and enhances distant metastases in Hgf‐Cdk4R24C C57BL/6 mice , 2011, International journal of cancer.
[35] G. Debes,et al. CCL8 and skin T cells—an allergic attraction , 2011, Nature Immunology.
[36] D. Rigel,et al. Epidemiology of melanoma. , 2010, Seminars in cutaneous medicine and surgery.
[37] W. Mars,et al. Hepatocyte Growth Factor Modulates Interleukin-6 Production in Bone Marrow Derived Macrophages: Implications for Inflammatory Mediated Diseases , 2010, PloS one.
[38] Jennifer Urbano Blackford,et al. Detecting Change in Biological Rhythms: A Multivariate Permutation Test Approach to Fourier‐Transformed Data , 2009, Chronobiology international.
[39] J. Li,et al. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix , 2005, Heredity.
[40] D. Schadendorf,et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. , 2019, The New England journal of medicine.
[41] J. Lunceford,et al. IFN-g – related mRNA profile predicts clinical response to PD-1 blockade , 2019 .
[42] J. Wolchok,et al. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. , 2015, The New England journal of medicine.